Draft:CT-996
| Submission declined on 22 September 2024 by Bhairava7 (talk). Creator not improved this draft per suggested by the other Afc reviewers, I've thought if the Template:Drugbox is added in the draft then it should be acceptable.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Comment: You may improve this by adding a Template:Drugbox Pygos (talk) 04:52, 2 September 2024 (UTC)
 | This article may be in need of reorganization to comply with Wikipedia's layout guidelines. (August 2024) |
CT-996 is an once daily oral small molecule GLP-1 agonist developed to treat obesity and type 2 diabetes.[1] It is designed with minimal-to-no beta-arrestin recruitment.[2] In a double-blind, randomized, placebo-controlled Phase I clinical trial participants averaged 6.1 percent placebo adjusted weight loss within four weeks.[3][4][5][6] The drug is being developed by Roche/Genentech after Roche's takeover of Carmot Therapeutics in January 2024.[7][8]
References
[edit]- ^ owenhaskins (2023-10-12). "Carmot's CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes". Bariatric News. Retrieved 2024-07-28.
- ^ "Clinical Trials | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
- ^ "Roche - Press release, July 17, 2024". www.roche.com. Retrieved 2024-07-26.
- ^ "CT-996 Demonstrates Significant Weight Loss in Patients with Obesity and Type 2 Diabetes". PharmExec. 2024-07-18. Retrieved 2024-07-26.
- ^ "ClinicalTrials.gov". clinicaltrials.gov. 14 June 2023. Retrieved 2024-07-28.
- ^ "Handelsblatt". www.handelsblatt.com (in German). Retrieved 2024-07-28.
- ^ Brody, Micaela (2024-01-29). "Carmot Therapeutics Announces Completion of Acquisition by Roche | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
- ^ Burger, Ludwig (December 4, 2023). "Roche joins race for obesity drugs with $2.7 billion Carmot deal". Reuters. Retrieved July 28, 2024.